Photobiomodulation for the Prevention of Oral Mucositis
NCT07290413 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 78
Last updated 2025-12-18
Summary
The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are:
Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photobiomodulation have optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT).
Participants will:
Be randomized to one of the three treatment arms Receive daily photobiomodulation therapy (from beginning of transplant conditioning through Day +20 after transplantation) Be evaluated for oral mucositis and symptoms daily Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler
Conditions
- Oral Mucositis
Interventions
- DEVICE
-
Photobiomodulation - INTRAORAL
Participants will receive intraoral photobiomodulation
- DEVICE
-
Photobiomodulation - EXTRAORAL
Participants will receive extraoral photobiomodulation
- DEVICE
-
Photobiomodulation - INTRAORAL and EXTRAORAL
Participants will receive intraoral and extraoral photobiomodulation
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 4 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-01
- Primary Completion
- 2026-12-31
- Completion
- 2027-05-31
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
NCT02342613 ·Status: COMPLETED ·Phase: PHASE1
-
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
NCT06102213 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
NCT05675930 ·Status: RECRUITING ·Phase: PHASE2
-
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers
NCT00003572 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
NCT00104065 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
NCT02396134 ·Status: COMPLETED ·Phase: PHASE2
-
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
NCT02120157 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
NCT00146614 ·Status: COMPLETED ·Phase: PHASE2
-
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
NCT00045305 ·Status: COMPLETED ·Phase: PHASE2
-
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)
NCT03959241 ·Status: COMPLETED ·Phase: PHASE3
-
Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease
NCT00871702 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
NCT00670423 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in BMT Recipients
NCT00189761 ·Status: COMPLETED ·Phase: PHASE2
-
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
NCT01962415 ·Status: RECRUITING ·Phase: PHASE2
-
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients
NCT04041219 ·Status: COMPLETED ·Phase: PHASE4
-
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies
NCT00795132 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
NCT01713400 ·Status: COMPLETED ·Phase: PHASE2
-
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
NCT00052520 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma
NCT00003196 ·Status: COMPLETED ·Phase: NA
-
Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant
NCT00008450 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
NCT00241358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
NCT03734601 ·Status: COMPLETED ·Phase: PHASE2
-
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
NCT00068523 ·Status: COMPLETED ·Phase: NA
-
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
NCT00816413 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Experimental Bone Marrow Transplant Protocol
NCT00061581 ·Status: COMPLETED ·Phase: PHASE2